Sorafenib (SOR) plus chemotherapy (CRx) for treatment (tx) of patients (pts) with HER2-negative locally advanced (adv) or metastatic (met) breast cancer (BC) and prior bevacizumab (BEV): Subgroup analysis of AC01B07 Meeting Abstract
| Authors: | Hudis, C. A.; Hermann, R. C.; Makari-Judson, G.; Isaacs, C.; Beck, J. T.; Kaklamani, V. G.; Rugo, H. S.; Wang, W.; Li, S.; Schwartzberg, L. S. |
| Abstract Title: | Sorafenib (SOR) plus chemotherapy (CRx) for treatment (tx) of patients (pts) with HER2-negative locally advanced (adv) or metastatic (met) breast cancer (BC) and prior bevacizumab (BEV): Subgroup analysis of AC01B07 |
| Meeting Title: | 16th ECCO - 36th ESMO - 30th ESTRO European Multidisciplinary Cancer Congress (EMCC 2011) |
| Journal Title: | European Journal of Cancer |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2011 Sep 23-27 |
| Meeting Location: | Stockholm, Sweden |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-09-01 |
| Start Page: | S338 |
| Language: | English |
| ACCESSION: | WOS:000295752801194 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(11)71468-X |
| Notes: | --- - Meeting Abstract: 5026 - European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care - SEP 23-27, 2011 - Stockholm, SWEDEN - "Source: Wos" |
